

Health Technology Clinical Committee

Date: November 21, 2014

Time: 8:00 am – 1:30 pm

Location: SeaTac Airport Conference Center

Adopted: January 16, 2015

Meeting materials and transcript are available on the HTA website at:

www.hca.wa.gov/hta/meetingmaterials/Forms/ExtMeetingMaterials

HTCC MINUTES

Members Present: C. Craig Blackmore, MD, MPH; Marie-Annette Brown, PhD, RN; David McCulloch, MD; Carson E. Odegard, DC, MPH; Richard C. Phillips, MD, MS, MPH; Seth Schwartz, MD, MPH; Michelle Simon, PhD, ND; Michael Souter, MB, Ch-B, DA, Christopher Standaert, MD; Kevin Walsh, MD

HTCC FORMAL ACTION

- 1. Call to Order:** Dr. Blackmore, Chair, called the meeting to order. Sufficient members were present to constitute a quorum.
- 2. July 11, 2014 Meeting Minutes:** Chair referred members to the draft minutes; motion to approve and second, and adopted by the committee.

Action: Ten committee members approved the July 11, 2014 meeting minutes. One member was absent.

3. Screening & Monitoring Tests for Osteopenia/ Osteoporosis

Agency Utilization and Outcomes:

Charissa Fotinos, MD, MSc, Deputy Chief Medical Director, WA Health Care Authority presented the state agency utilization rates for Screening & Monitoring Tests for Osteopenia/ Osteoporosis to the committee. The full presentation is published with [November 21, meeting materials](#).

Scheduled and Open Public Comments: The Chair called for public comments. No scheduled comments were requested. Open public comments were presented by:

Donna Fiorentino, Legislative Counsel for the International Society for Clinical Densitometry

Vendor Report and HTCC Q & A:

The Chair introduced the clinical expert for Screening & Monitoring Tests for Osteopenia/ Osteoporosis, Christopher Shuhart, MD, MHA, CCD, Swedish Physicians Bone Health and Osteoporosis.

Final

Teresa L. Rogstad, MPH, of Hayes, Inc, presented the evidence review addressing Screening & Monitoring Tests for Osteopenia/ Osteoporosis. The full presentation is published with [November 21, meeting materials](#).

Committee Discussion and Decision:

The HTCC reviewed and considered the Screening & Monitoring Tests for Osteopenia/ Osteoporosis technology assessment report and information provided by the state agencies. They also heard comments from the evidence reviewer, the clinical expert, the public, and agency medical directors. The committee considered all the evidence and gave greatest weight to the evidence it determined, based on objective factors, to be the most valid and reliable. [See transcript for full committee deliberations.]

HTCC Committee Coverage Determination Vote			
	Not Covered	Covered Unconditionally	Covered Under Certain Conditions
Screening for Osteopenia/ Osteoporosis	0	0	10

Discussion:

The Chair called for discussion of the evidence for conditional coverage of DXA scanning to determine bone mineral density and osteoporosis. Conditions of coverage for **Screening for Osteopenia/ Osteoporosis** were discussed and proposed. Following discussion of the proposed conditions for coverage the committee voted for coverage under certain conditions. The following conditions were discussed and approved by a majority of the clinical committee:

Limitations of Coverage:

Initial Screening:

Asymptomatic women

- Women ≥ 65
Or
- Younger women with equivalent ten year fracture risk to women age 65 as calculated by FRAX or other validated scoring tool

Men or women

- Long term glucocorticosteroids (incorporate FRAX definition),
- Androgen deprivation,
- Other conditions known to be associated with low bone mass

Repeat Screening:

- T-score > -1.5 , 15 years to next screening test
- T-score -1.5 to -1.99 , 5 years to next screening test
- T-score < -2.0 , 1 year to next screening test

- Or
- Use of medication associated with low bone mass or presence of a condition known to be associated with low bone mass

Monitoring Treatment:

- Once treatment for osteoporosis has begun, serial monitoring is not covered
- Development of a fragility fracture alone is not a covered indication

Action

The committee checked for availability of a Medicare coverage decision. There is a national coverage determination (NCD) for *Bone (Mineral) Density Studies*. A document on *Bone Mass Measures* in the Manual System states that effective January 1, 2007, bone mass measurement is covered, generally every 2 years but subject to certain conditions. Neither the NCD nor the Manual System provides the rationale or evidence base for these policies.

The committee reviewed and considered practice guideline recommendations issued by the United States Preventive Services Task Force, American Association of Clinical Endocrinologists, American College of Gastroenterology, American College of Obstetricians and Gynecologists, American College of Physicians, American College of Preventive Medicine, American College of Radiology, European Urological Association, Institute for Clinical Systems Improvement, International Society for Clinical Densitometry, North American Menopause Society, and National Osteoporosis Foundation.

The Chair directed HTA staff to prepare a draft coverage determination document for the topic.

The Chair called for further comments. No further comments on Screening & Monitoring Tests for Osteopenia/ Osteoporosis.

6. Josh Morse, HTA Program Director presented information regarding the six HTA reviews currently in progress.
7. **Meeting adjourned.**